Breast

3-D Mammography Significantly Reduces Breast Biopsy Rates

(RSNA) Mar 19, 2019 - The use of digital breast tomosynthesis (DBT), also known as 3-D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study published in the journal Radiology.

read press release

Breast Density Assessment Varies Greatly By Screening Method And Race

(RSNA) Mar 19, 2019 - Fewer women are assigned to a dense breast category when evaluated with advanced mammographic screening technologies compared to standard digital mammography, according to a new study published in the journal Radiology.

read press release

Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients, According to Researchers from Duke University

(NCCN) Mar 19, 2019 - New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score (RS) testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy.

read press release

CancerIQ Platform More than Doubles Number of Patients Identified as Eligible for MRI Surveillance to Detect Cancer Earlier

(Markets Insider) Mar 17, 2019 - Riverside Healthcare and Cancer IQ, Inc. presented the results of a 24-month study of a high-risk program to screen and identify women at elevated risk for hereditary cancer in the mammography setting at the National Consortium of Breast Centers 29th annual Interdisciplinary Breast Center Conference today in Las Vegas.

read article

New Susan G. Komen® Study Unveils High Cost of Diagnostic Tests for Breast Cancer Serves as a Barrier to Needed Care

(Susan G. Komen) Mar 14, 2019 - Study shows women delay or avoid diagnostic exams due to high out-of-pocket costs.

read press release

Molecular Data Categorizes Breast Cancers

(Stanford Medicine) Mar 13, 2019 - Some breast cancers return decades later. Now, researchers at Stanford, joined by collaborators at several other institutions, have subcategorized tumors to predict recurrence, guide treatment decisions and improve drug development.

read press release

Drug Could Alleviate Side Effects Of Chemo For Breast Cancer Patients

(Stanford Medicine) Mar 14, 2019 - Stanford researchers have found a way to predict who will suffer heart problems from a common breast-cancer drug, as well as identified an FDA-approved medication that could mitigate those side effects.

read press release

Study: Free Fatty Acids Appear To Rewire Cells To Promote Obesity-Related Breast Cancer

(University of Illinois/Ilinois News Bureau) Mar 13, 2019 - Free fatty acids in the blood are linked with higher rates of estrogen-receptor positive breast cancer in obese postmenopausal women, according to a new study.

read press release

Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

(Yahoo! Finance) Mar 14, 2019 - MARIO-3 will evaluate IPI-549 with Tecentriq and Abraxane® in front-line triple negative breast cancer and IPI-549 with Tecentriq and Avastin® in front-line renal cell cancer.

read article

Atossa Genetics Announces FDA Approval of Endoxifen for "Expanded Access" as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

(Yahoo! Finance) Mar 14, 2019 - Atossa Genetics Inc. today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient.

read article

Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

(MarketWatch) Mar 12, 2019 - Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination with gemcitabine vs. gemcitabine alone for patients with surgically resected pancreatic cancer. Celgene Corporation today announced two updates for ABRAXANE [®] (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer. Genentech, a member of the Roche Group, recently announced the accelerated approval of TECENTRIQ [®] (atezolizumab) in combination with ABRAXANE [®] for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-approved test.

read article

Number of Pregnancies Influences Breast Cancer Risk for Women with BRCA Mutations

(Columbia) Mar 11, 2019 - Researchers at Columbia University Mailman School of Public Health and the Institut National de la Santé et de la Recherche Médicale in Paris confirm the lower risk of breast cancer from multiple pregnancies and from breast feeding seen in average risk women extends to those at the highest risk of breast cancer, according to the largest prospective study of BRCA1 and BRCA2 mutations carriers to date.

read article

Treatment Guidelines For Breast Implant-Associated Lymphoma (BIA-ALCL)

(UCCC/Colorado Cancer Blogs) Mar 12, 2019 - An article recently published in Aesthetic Surgery Journal formalizes the treatment strategy for this diagnosis, offering clear guidelines for plastic and oncologic surgeons.

read article

FDA Approves Pfizer's Trastuzumab Biosimilar, Trazimera

(The Center for Biosimilars) Mar 11, 2019 - The FDA has approved Pfizer’s trastuzumab-qyyp (Trazimera), a biosimilar referencing Herceptin. "This is an important milestone in the [United States] which both adds to our growing portfolio of oncology treatments and has the potential to improve access to cancer care,” said Andy Schmeltz, global president of Pfizer Oncology, in a statement. “We are proud to be able to offer treatment options that can help address the diverse needs of patients.”

read article

U.S. FDA Approves Pfizer’s Oncology Biosimilar Trazimera™ (Trastuzumab-QYYP), A Biosimilar To Herceptin®

(Pfizer) Mar 11, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab), for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. “This is an important milestone in the U.S. which both adds to our growing portfolio of oncology treatments and has the potential to improve access to cancer care,” said Andy Schmeltz, Global President, Pfizer Oncology. “We are proud to be able to offer treatment options that can help address the diverse needs of patients.”

read corporate press release

Vaccine For HER2 Breast Cancer Shows Early Promise

(Duke Cancer Institute) Mar 11, 2019 - A vaccine developed by Duke Cancer Institute researchers has shown early promise in targeting the HER2 protein that fuels a deadly form of breast cancer.

read article

Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer

(NCI/Cancer Currents Blog) Mar 11, 2019 - A drug commonly used for bone marrow transplants may improve immunotherapy.

read article

Repurposing Older Drugs Could Raise New Hope For Breast Cancer Treatment

(UChicago News) Mar 11, 2019 - The lack of better medicines for triple negative cancers prompted a team of researchers to look for novel drug targets and new ways to disrupt disease-causing pathways.

read article

FDA Grants Roche’s Tecentriq In Combination With Abraxane Accelerated Approval For People With PD-L1-positive, Metastatic Triple-Negative Breast Cancer

(Roche) Mar 11, 2019 - Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The FDA’s Accelerated Approval Programme allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.

read corporate press release

Roche’s VENTANA PD-L1 (SP142) Assay Approved As First Companion Diagnostic To Identify Triple-Negative Breast Cancer Patients Eligible For Treatment With Tecentriq In Combination With Abraxane

(Roche) Mar 11, 2019 - PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer. Each year about 300,000 women are diagnosed globally with triple-negative breast cancer, an aggressive disease with limited treatment options that represents 15 percent of all breast cancer cases. This approval is an important step in Roche’s personalized healthcare strategy to fit treatments to patients who can benefit most from a specific medicine.

read corporate press release
Next Page